eluxadoline sold brand names viberzi medication taken mouth treatment diarrhea abdominal pain individuals diarrheapredominant irritable bowel syndrome approved use united states drug originated janssen pharmaceutica developed actavis drug contraindicated case common adverse effects constipation nausea rates discontinuation due constipation low eluxadoline placebo rare adverse effects fatigue bronchitis viral gastroenteritis rare serious adverse effects include pancreatitis general incidence higher incidence mg dose mg dose risk even greater gall bladder medication recommended march us food drug administration issued safety alert eluxadoline concerning increased risk serious pancreatitis patients without fda review found patients spasm sphincter oddi may lead severe fda reported cases symptoms occurred one two doses recommended dosage patients without gallbladder two deaths associated eluxadoline reported february occurred patients without elevated concentrations eluxadoline observed coadministration inhibitors transporter protein also concurrent use drugs cause constipation preferred eluxadoline increases concentrations drugs bcrp substrates also coadministration eluxadoline rosuvastatin may increase risk eluxadoline μ κopioid receptor agonist δopioid receptor acts locally enteric nervous system possibly decreasing adverse effects central nervous vitro studies eluxadoline found transported bsep highest concentrations tested ngml larger observed cmax highest therapeutic dose mg however transported organic anion transporter pgp pglycoprotein bcrp multidrug resistanceassociated protein accumulation eluxadoline observed indicating drug substrate eluxadoline found inhibit bcrp bsep transport probe substrates inhibited transport probe substrates pgp also vitro studies observed eluxadoline vivo substrate finally inhibition induction cytochrome enzymes following mg dose eluxadoline cmax ngml auc nghml eluxadoline linear pharmacokinetics accumulation upon repeated twice daily dosing taking eluxadoline high fat meal decreased cmax auc synthesis eluxadoline extensively discussed patent title process preparation opioid modulators published sept httpsenwikipediaorgwikieluxadoline